PPCH, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers is entering a pivotal stage that could turn cancer from a life-ending illness to a chronic, treatable illness with its lead drug, PRP. PRP aims to prevent tumor recurrence and metastasis in solid tumors. The success of their lead product will change the way we view cancer.
PROPANC BIOPHARMA, INC.’S LATEST MILESTONES
The name change announced earlier this month is official, as they are now operating as Propanc Biopharma Inc. (PPCHD). This name change represents significant achievements the company has seen over the last two years. This company has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body.
• Approved patent allowance in the US for lead product PRP which aims to prevent tumor recurrence and metastasis in solid tumors.
• Successful completion of low dose group for GLP-compliant 28-Day repeat-dose toxicity study.
• Currently in formal preclinical development and progressing toward First-In-Man studies.
• Effectuated a reverse stock split with plans to up-list the company and completed a 1-for-250 reverse split.
• CEO, James Nathanielsz, published two articles in Pharma Trade Media.
• Their patent portfolio has grown to six patent applications covering several important discoveries regarding proenzymes and their anti-cancer effects.
• International Research and Development Partnerships with Universities and Contract Research Organizations in the US, Spain, Australia, and the UK.
• Development of Investigational New Drug (IND) Product Manufacture of PRP for human use.
With PPCH’s success infiltrating the US patent market, two featured articles were published by PPCH’s CEO, James Nathanielsz, in Pharma Trade Media. These articles highlight ways in which changes to the FDA could cure cancer. PPCH’s recent successes in toxicity testing, name change, reverse stock split, and preclinical development of the First-In-Man studies, has positioned them at the forefront of exciting new innovative approaches within the cancer research industry.
“New and improved standards of cancer care need to be supported by a rigorous, yet flexible regulatory framework. Practical measures can be taken to fast track new products which could see cancer become more of a chronic illness than a life-ending one.”
Last year’s highlights certainly set the tone for this past quarter.
REVISTING THE HIGHLIGHTS OF 2016
• Prepared and submitted four new patents relating to the dosing, anti-cancer effects and mechanisms of the two proenzymes against various cancers in Australia and Spain.
• Executed a manufacturing agreement with AmatsiQBiologials in Belgium beginning the process for the finished product of PRP for human use.
• Completed 14-day, dose range toxicity study in rats determining maximum toleration for further studies.
• Developed an enzyme linked immunosorbent assay (ELISA) method.
• Developed and validated a new IR (infrared) dye-labelled detection method for typsinogen and chymotrypsinogen.
• Commenced the in-life phase of a GLP-compliant, 28-day repeat dose-toxicity study for PRP in rats, which is expected to help define the safe starting dose in advanced cancer patients for the first-in-man studies.
IN OTHER BIOTECH NEWS…
Tune in on Friday, May 5th as ImmunoGen, Inc. (IMNO) hosts a conference call scheduled for 8am to discuss its first quarter 2017 financial results. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology.
Spectrum Pharmaceuticals, Inc. (SPPI) and its subsidiaries have six FDA-approved oncology/hematology products and two products in late-stage development. Recently, the company presented three abstracts on ROLONTIS (eflapegrastim) and BELEODAQ (belinostat) at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
La Jolla Pharmaceutical (LJPC) announced top-line results only for LJPC-501, a treatment for patients with catecholamine resistant hypotension.
Array Biopharma (ARRY) is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Shares of the company fell sharply last month after they announced the withdrawal of its new drug application (NDA).
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States